FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, generally known as "smoker's lung." Dupixent is the first biologic medicine approved in the U.S. to treat these patients. Also Read: Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease. The FDA approval is based on dat ...